Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti–PD-L1, PD-1, and CTLA-4 mAbs)...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jonathan Rios-Doria, Nicholas Durham, Leslie Wetzel, Raymond Rothstein, Jon Chesebrough, Nicholas Holoweckyj, Wei Zhao, Ching Ching Leow, Robert Hollingsworth
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2015-08-01
Col·lecció:	Neoplasia: An International Journal for Oncology Research
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1476558615001001
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!